Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults

Neurology

Volumn 77, Issue 10, 2011, Pages 951-958

  Kantarci, K ^a   Lowe, V ^a   Przybelski, S A ^a   Senjem, M L ^a   Weigand, S D ^a   Ivnik, R J ^a   Roberts, R ^a   Geda, Y E ^a   Boeve, B F ^a   Knopman, D S ^a   Petersen, R C ^a   Jack Jr , C R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CREATINE; INOSITOL; PITTSBURGH COMPOUND B; CHOLINE; CREATININE;

ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MEMORY; METABOLITE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION BASED CASE CONTROL STUDY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGIC TEST; PSYCHOMETRY; SENESCENCE; SEX DIFFERENCE; WECHSLER INTELLIGENCE SCALE; WECHSLER MEMORY SCALE; AGED; BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; HEALTH SURVEY; MALE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN STABILITY; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; CHOLINE; COGNITION; COGNITION DISORDERS; CREATININE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PROTEIN STABILITY;

EID: 80055073182     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822dc7e1     Document Type: Article

References (40)

1. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:6-15. (Pubitemid 44356888)
2. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008;248:210-220.
3. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000;55:210-217. (Pubitemid 30604620)
4. Chao LL, Schuff N, Kramer JH, et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005;64:282-289.
5. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66:718-722. (Pubitemid 43739827)
6. den Heijer T, Sijens PE, Prins ND, et al. MR spectroscopy of brain white matter in the prediction of dementia. Neurology 2006;66:540-544. (Pubitemid 43739884)
7. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
8. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69. (Pubitemid 351311727)
9. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology 2010;75:889-897.
10. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994;31:365-373. (Pubitemid 24108265)
11. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680. (Pubitemid 351294719)
12. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of 18FFDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878-886.
13. Schemper M. Non-parametric partial association revisited. J R Stat Soc Ser D 1991;40:73-76.
14. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
15. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130: 2837-2844. (Pubitemid 350033975)
16. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221-229.
17. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004;1003:26-35. (Pubitemid 38317081)
18. Catani M, Cherubini A, Howard R, et al. 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001;12:2315-2317. (Pubitemid 32682179)
19. Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a 1H MRS study. Neurology 2001;57:626-632. (Pubitemid 32782989)
20. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13: 981-989. (Pubitemid 23067586)
21. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289-298. (Pubitemid 24258162)
22. Fisher SK, Novak JE, Agranoff BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 2002;82: 736-754.
23. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1989;1004:169-179. (Pubitemid 19193177)
24. Marjanska M, Curran GL, Wengenack TM, et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 2005;102:11906-11910. (Pubitemid 41170823)
25. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998;8:809-822. (Pubitemid 28532518)
26. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a nonspecific imaging marker of amyloid-beta (Abeta) peptiderelated cerebral amyloidosis. Brain 2007;130:2607-2615. (Pubitemid 47511709)
27. Kantarci K, Yang C, Schneider JA, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging Epub 2010 Oct 18.
28. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131: 1630-1645. (Pubitemid 351806448)
29. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-339. (Pubitemid 27465015)
30. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007;80:S146-S152.
31. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 2000;107:1027-1063.
32. MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996;53:167-174. (Pubitemid 26055264)
33. Wurtman RJ, Blusztajn JK, Maire JC. Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease: a hypothesis. Neurochem Int 1985;7:369-372. (Pubitemid 15116219)
34. Kantarci K, Petersen RC, Boeve BF, et al. 1H MR spectroscopy in common dementias. Neurology 2004;63: 1393-1398.
35. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 1997; 154:1459-1461. (Pubitemid 27415619)
36. Jessen F, Block W, Träber F, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001;57:930-932. (Pubitemid 32845528)
37. Kantarci K, Smith GE, Ivnik RJ, et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 2002;8:934-942. (Pubitemid 35355862)
38. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;56:592-598. (Pubitemid 32209990)
39. Kantarci K, Weigand SD, Petersen RC, et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007;28:1330-1339. (Pubitemid 47081237)
40. Schott JM, Frost C, MacManus DG, Ibrahim F, Waldman AD, Fox NC. Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain 2010;133:3315-3322.